A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection - Trial NCT06384131
Access comprehensive clinical trial information for NCT06384131 through Pure Global AI's free database. This Phase 1 trial is sponsored by Assembly Biosciences and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assembly Biosciences
Timeline & Enrollment
Phase 1
Apr 30, 2024
Apr 22, 2025
Primary Outcome
Primary Outcome Measure
Summary
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety,
 PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis
 B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The
 study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50
 subjects, randomized 8:2 to receive ABI-4334 or placebo.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06384131
Non-Device Trial